MARCKS is a New Prognostic Biomarker in Hepatocellular Carcinoma

Int J Gen Med. 2023 May 1:16:1603-1619. doi: 10.2147/IJGM.S408651. eCollection 2023.


Background: Hepatocellular carcinoma (HCC) is one of the most common type of cancers, but there is still a lack of known biomarkers for the effective diagnosis or prognosis of HCC. Myristoylated alanine-rich C-kinase substrate (MARCKS) is a substrate of protein kinase C, which was located in the cell plasma membrane. The purpose of our study was to evaluate the role of MARCKS in HCC.

Methods: The role of MARCKS in HCC was explored by bioinformatics and experiment.

Results: We demonstrated that MARCKS expression was significantly elevated in HCC datasets of TCGA. MARCKS was up-regulated in tumor sample in HCC. Functional enrichment indicated that MARCKS-related differentially expressed genes (DEGs) were mainly enriched in cell junction tissue, response to growth factors and cell population proliferation. Tumor and ECM-receptor interactions related pathways were enriched by the KEGG. MARCKS expression in HCC patients was higher in females, younger individuals, and those at worse clinical stages. Cox regression analysis showed that MARCKS expression was a risk factor for overall survival and disease-specific survival of patients.

Conclusion: MARCKS was up-regulated in HCC, may play a crucial role in HCCs, and has prognostic value for clinical outcomes.

Keywords: HCC; TCGA; myristoylated alanine-rich C-kinase substrate; prognostic value.

Grants and funding

This study was supported by grants from the National Natural Science Foundation of China (No.82173371, 81802446), project tsqn.201909192 supported by Tai Shan Young Scholar Foundation of Shandong Province, project ZR2019BH050, ZR2020YQ59, ZR202103020202 supported by Shandong Provincial Natural Science Foundation, project 202003031182, 202003031183, 202104010323 supported by the Project of Medicine Health and Technology Development Plan of Shandong Province, the Miaopu Research of the Affiliated Hospital of Jining Medical University (No. MP-ZD-2020-005).